Receptor and channel heteromers as pain targets

Pharmaceuticals

Volumn 5, Issue 3, 2012, Pages 249-278

  Berg, Kelly A ^a   Patwardhan, Amol M ^b   Akopian, Armen N ^a,c  

^a University of Texas Health Science Center at San Antonio   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Channels; Heteromers; Pain; Receptors; Sensory neurons

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; 6 FLUORO 2,9 DIHYDRO 9 METHYL 2 PHENYL 4 (1 PYRROLIDINYLCARBONYL) 1H PYRIDO[3,4 B]INDOL 1 ONE; 6' GUANIDINONALTRINDOLE; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ALPHA 2A ADRENERGIC RECEPTOR; CANNABINOID RECEPTOR; CLONIDINE; DELTA OPIATE RECEPTOR; DIAZEPAM; DRONABINOL; EPIBATIDINE; G PROTEIN COUPLED RECEPTOR; GASTRIN RELEASING PEPTIDE RECEPTOR; GLUTAMATE RECEPTOR; IFENPRODIL; KAPPA OPIATE RECEPTOR; LIGAND GATED ION CHANNEL; MORPHINE; MU OPIATE RECEPTOR; N NAPHTHOYL A NALTREXAMINE; NALTREXAMINE DERIVATIVE; NALTRINDOLE; NICOTINIC RECEPTOR; OPIATE RECEPTOR; PURINERGIC P2X RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; BRAIN ISCHEMIA; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; NEUROPATHIC PAIN; NONHUMAN; PAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84858858915     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph5030249     Document Type: Review

References (205)

1. Casado, V.; Cortésa, A.; Mallola, J.; Pérez-Capotea, K.; Ferréb, S.; Lluisa, C.; Francoa, R.; Canela, E.I. GPCR homomers and heteromers: A better choice as targets for drug development than GPCR monomers? Pharmacol. Ther. 2009, 124, 248-257.
2. Mathie, A.; Clarke, C.E.; Ranatunga, K.M.; Veale, E.L. What are the roles of the many different types of potassium channel expressed in cerebellar granule cells? Cerebellum 2003, 2, 11-25.
3. Dunah, A.W.; Yasuda, R.P.; Luo, J.H.; Wang, Y.H.; Prybylowski, K.L.; Wolfe, B.B. Biochemical studies of the structure and function of the N-methyl-D-aspartate subtype of glutamate receptors. Mol. Neurobiol. 1999, 19, 151-179.
4. Akopian, A.N. Regulation of nociceptive transmission at the periphery via TRPA1-TRPV1 interactions. Curr. Pharm. Biotechnol. 2011, 12, 89-94.
5. Ferre, S.; Baler, R.; Bouvier, M.; Caron, M.G.; Devi, L.A.; Durroux, T.; Fuxe, K.; George, S.R.; Javitch, J.A.; Lohse, M.J.; et al. Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol. 2009, 5, 131-134.
6. Smith, N.J.; Milligan, G. Allostery at G protein-coupled receptor homo- and heteromers: Uncharted pharmacological landscapes. Pharmacol. Rev. 2010, 62, 701-725.
7. Schaefer, M. Homo- and heteromeric assembly of TRP channel subunits. Pflugers Arch. 2005, 451, 35-42.
8. Gotti, C.; Moretti, M.; Gaimarri, A.; Zanardi, A.; Clementi, F.; Zoli, M. Heterogeneity and complexity of native brain nicotinic receptors. Biochem. Pharmacol. 2007, 74, 1102-1111.
9. Franco, R.; Lluis, C.; Canela, E.I.; Mallol, J.; Agnati, L.; Casadó, V.; Ciruela, F.; Ferré, S.; Fuxe, K. Receptor-receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins. J. Neural. Transm. 2007, 114, 93-104.
10. Salas, M.M.; Hargreaves, K.M.; Akopian, A.N. TRPA1-mediated responses in trigeminal sensory neurons: Interaction between TRPA1 and TRPV1. Eur. J. Neurosci. 2009, 29, 1568-1578.
11. Enz, R.; Cutting, G.R. Molecular composition of GABAC receptors. Vision Res. 1998, 38, 1431-1441.
12. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S.F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51, 7-61.
13. Paoletti, P. Molecular basis of NMDA receptor functional diversity. Eur. J. Neurosci. 2011, 33, 1351-1365.
14. Gavva, N.R.; Tamir, R.; Qu, Y.S.; Klionsky, L.; Zhang, T.J.; Immke, D.; Wang, J.; Zhu, D.; Vanderah, T.W.; Porreca, F.; et al. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo [b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J. Pharmacol. Exp. Ther. 2005, 313, 474-484.
15. McGaraughty, S.; Chu, K.L.; Faltynek, C.R.; Jarvis, M.F. Systemic and site-specific effects of A- 425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats. J. Neurophysiol. 2006, 95, 18-25.
16. Wang, H.L.; Katon, J.; Balan, C.; Bannon, A.W.; Bernard, C.; Doherty, E.M.; Dominguez, C.; Gavva, N.R.; Gore, V.; Ma V. et al. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. J. Med. Chem. 2007, 50, 3528-3539.
17. Gavva, N.R. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol. Sci. 2008, 29, 550-557.
18. Starowicz, K.; Cristino, L.; Di Marzo, V. TRPV1 receptors in the central nervous system: Potential for previously unforeseen therapeutic applications. Curr. Pharm. Des. 2008, 14, 42-54.
19. Palazzo, E.; Luongo, L.; de Novellis, V.; Berrino, L.; Rossi, F.; Maione, S. Moving towards supraspinal TRPV1 receptors for chronic pain relief. Mol. Pain 2011, 6, 66.
20. Cui, M.; Honore, P.; Zhong, C.; Gauvin, D.; Mikusa, J.; Hernandez, G.; Chandran, P.; Gomtsyan, A.; Brown, B.; Bayburt, E.K. et al. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J. Neurosci. 2006, 26, 9385-9393.
21. Gavva, N.R.; Bannon, A.W.; Surapaneni, S.; Hovland, D.N., Jr.; Lehto, S.G.; Gore, A.; Juan, T.; Deng, H.; Han, B.; Klionsky L. et al. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J. Neurosci. 2007, 27, 3366-3374.
22. Staruschenko, A.; Jeske, N.A.; Akopian, A.N. Contribution of TRPV1-TRPA1 interaction to the single channel properties of the TRPA1 channel. J. Biol. Chem. 2010, 285, 15167-15177.
23. Hellwig, N.; Albrecht, N.; Harteneck, C.; Schultz, G.; Schaefer, M. Homo- and heteromeric assembly of TRPV channel subunits. J. Cell. Sci. 2005, 118, 917-928.
24. Cheng, W.; Sun, C.; Zheng, J. Heteromerization of TRP channel subunits: Extending functional diversity. Protein Cell 2010, 1, 802-810.
25. Akopian, A.N.; Ruparel, N.B.; Jeske, N.A.; Hargreaves, K.M. Transient receptor potential TRPA1 channel desensitization in sensory neurons is agonist dependent and regulated by TRPV1-directed internalization. J. Physiol. 2007, 583, 175-193.
26. Hasbi, A.; O'Dowd, B.F.; George, S.R. Dopamine D1-D2 receptor heteromer signaling pathway in the brain: Emerging physiological relevance. Mol. Brain 2010, 4, 26.
27. 2+. Neuroscience 2010, 171, 1109-1119.
28. Jacoby, E.; Bouhelal, R.; Gerspacher, M.; Seuwen, K. The 7 TM G-protein-coupled receptor target family. ChemMedChem 2006, 1, 760-782.
29. Pan, H.L.; Wu, Z.-Z.; Zhou, H.-Y.; Chen, S.-R.; Zhang, H.-M.; Li, D.-P. Modulation of pain transmission by G-protein-coupled receptors. Pharmacol. Ther. 2008, 117, 141-161.
30. Vischer, H.F.; Watts, A.O.; Nijmeijer, S.; Leurs, R. G protein-coupled receptors: Walking hand-in-hand, talking hand-in-hand? Br. J. Pharmacol. 2011, 163, 246-260.
31. Rozenfeld, R.; Devi, L.A. Receptor heteromerization and drug discovery. Trends Pharmacol. Sci. 2010, 31, 124-130.
32. Milligan, G. G protein-coupled receptor hetero-dimerization: Contribution to pharmacology and function. Br. J. Pharmacol. 2009, 158, 5-14.
33. Milligan, G. The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. Curr. Opin. Pharmacol. 2010, 10, 23-29.
34. Fuxe, K.; Marcellino, D.; Borroto-Escuela, D.O.; Frankowska, M.; Ferraro, L.; Guidolin, D.; Ciruela, F.; Agnati, L.F. The changing world of G protein-coupled receptors: From monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions. J. Recept. Signal Transduct. Res. 2010, 30, 272-283.
35. Rozenfeld, R.; Devi, L.A. Exploring a role for heteromerization in GPCR signalling specificity. Biochem. J. 2011, 433, 11-18.
36. Han, Y.; Moreira, I.S.; Urizar, E.; Weinstein, H.; Javitch, J.A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 2009, 5, 688-695.
37. Keov, P.; Sexton, P.M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors: A pharmacological perspective. Neuropharmacology 2011, 60, 24-35.
38. Fuxe, K.; Marcellino, D.; Leo, G.; Agnati, L.F. Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis. Curr. Opin. Pharmacol. 2010, 10, 14-22.
39. Stein, C.; Clarkb, J.D.; Ohc, U.; Vaskod, M.R.; Wilcoxe, G.L.; Overlande, A.C.; Vanderahf, T.W.; Spencer, R.H. Peripheral mechanisms of pain and analgesia. Brain Res. Rev. 2009, 60, 90-113.
40. Stein, C.; Lang, L.J. Peripheral mechanisms of opioid analgesia. Curr. Opin. Pharmacol. 2009, 9, 3-8.
41. Ji, R.R.; Zhang, Q.; Law, P.Y.; Low, H.H.; Elde, R.; Hokfelt, T. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J. Neurosci. 1995, 15, 8156-8166.
42. Rau, K.K.; Caudle, R.M.; Cooper, B.Y.; Johnson, R.D. Diverse immunocytochemical expression of opioid receptors in electrophysiologically defined cells of rat dorsal root ganglia. J. Chem. Neuroanat. 2005, 29, 255-264.
43. Wang, H.B.; Zhao, B.; Zhong, Y.Q.; Li, K.C.; Li, Z.Y.; Wang, Q.; Lu, Y.J.; Zhang, Z.N.; He, S.Q.; Zheng, H.C. et al. Coexpression of delta- and mu-opioid receptors in nociceptive sensory neurons. Proc. Natl. Acad. Sci. USA 2010, 107, 13117-13122.
44. Raynor, K.; Kong, H.; Chen, Y.; Yasuda, K.; Yu, L.; Bell, G.I.; Reisine, T. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol. 1994, 45,330-334.
45. Traynor, J.R.; Elliott, J. Delta-Opioid receptor subtypes and cross-talk with mu-receptors. Trends Pharmacol. Sci. 1993, 14, 84-86.
46. Dietis, N.; Rowbotham, D.J.; Lambert, D.G. Opioid receptor subtypes: Fact or artifact? Br. J. Anaesth. 2011, 107, 8-18.
47. Abdelhamid, E.E.; Sultana, M.; Portoghese, P.S.; Takemori, A.E. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 1991, 258, 299-303.
48. Zhu, Y.; King, M.A.; Schuller, A.G.P.; Nitsche, J.F.; Reidl, M.; Elde, R.P.; Unterwald, E.; Pasternak, G.W.; Pintar, J.E. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 1999, 24, 243-252.
49. Gendron, L.; Pintar, J.E.; Chavkin, C. Essential role of MU opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia. Neuroscience 2007, 150, 807-817.
50. George, S.R.; Fan, T.; Xie, Z.; Tse, R.; Tam, V.; Varghese, G.; O'Dowd, B.F. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 2000, 275, 26128-26135.
51. Gomes, I.; Jordan, B.A.; Gupta, A.; Trapaidze, N.; Nagy, V.; Devi, L.A. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J. Neurosci. 2000, 20, RC110.
52. Scherrer, G.; Imamachi, N.; Cao, Y.-Q.; Contet, C.; Mennicken, F.; O'Donnell, D.; Kieffer, B.L.; Basbaum, A.I. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 2009, 137, 1148-1159.
53. Gupta, A.; Mulder, J.; Gomes, I.; Rozenfeld, R.; Bushlin I.;, Ong, E.; Lim, M.; Maillet, E.; Junek, M.; Cahill, C.M. et al. Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci. Signal. 2010, 3, ra54.
54. Gomes, I.; Gupta, A.; Filipovska, J.; Szeto, H.H.; Pintar, J.E.; Devi, L.A. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc. Natl. Acad. Sci. USA 2004, 101, 5135-5139.
55. Law, P.Y.; Erickson-Herbrandson, L.J.; Zha, Q.Q.; Solberg, J.; Chu, J.; Sarre, A.; Loh, H.H. Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J. Biol. Chem. 2005, 280, 11152-11164.
56. Gomes, I.; IJzerman, A.P.; Ye, K.; Maillet, E.L.; Devi, L.A. G protein-coupled receptor heteromerization: A role in allosteric modulation of ligand binding. Mol. Pharmacol. 2011, 79, 1044-1052.
57. Christopoulos, A.; Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 2002, 54, 323-374.
58. Gregory, K.J.; Sexton, P.M. Christopoulos, A. Overview of receptor allosterism. Curr. Protoc. Pharmacol. 2010, 51, 1.21.1-1.21.34.
59. Pierce, K.L.; Premont, R.T.; Lefkowitz, R.J. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 2002, 3, 639-650.
60. Rozenfeld, R.; Devi, L.A. Receptor heterodimerization leads to a switch in signaling: beta-Arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J. 2007, 21, 2455-2465.
61. Bohn, L.M.; Lefkowitz, R.J.; Caron, M.G. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J. Neurosci. 2002, 22, 10494-10500.
62. Fan, T.; Varghese, G.; Nguyen, T.; Tse, R.; O'Dowd, B.F.; George, S.R. A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J. Biol. Chem. 2005, 280, 38478-38488.
63. Hasbi, A.; Nguyen, T.; Fan, T.; Cheng, R.; Rashid, A.; Alijaniaram, M.; Rasenick, M.M.; O'Dowd, B.F.; George, S.R. Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: Coregulation by agonists. Biochemistry 2007, 46, 12997-13009.
64. Daniels, D.J.; Lenard, N.R.; Etienne, C.L.; Law, P.-Y.; Roerig, S.C.; Philip, S. Portoghese Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. USA 2005, 102, 19208-19213.
65. Lenard, N.R.; Daniels, D.J.; Portoghese, P.S.; Roerig, S.C. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opiold receptor antagonist pharmacophores. Eur. J. Pharmacol. 2007, 566, 75-82.
66. Jordan, B.A.; Devi, L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999, 399, 697-700.
67. Waldhoer, M.; Fong, J.; Jones, R.M.; Lunzer, M.M.; Sharma, S.K.; Kostenis, E.; Portoghese, P.S.; Whistler, J.L. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. USA 2005, 102, 9050-9055.
68. Ansonoff, M.A.; Portoghese, P.S.; Pintar, J.E. Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands. Psychopharmacology (Berl.) 2010, 210, 161-168.
69. Berg, K.A.; Rowan, M.P.; Gupta, A.; Sanchez, T.A.; Silva, M.; Gomes, I.; McGuire, B.A.; Portoghese, P.S.; Hargreaves, K.M.; Devi, L.A. et al. Allosteric Interactions between delta and kappa opioid receptors in peripheral sensory neurons. Mol. Pharmacol. 2011, doi:10.1124/mol.111.072702.
70. Ansonoff, M.A.; Wen, T.; Pintar, J.E. Kappa2 opioid receptor subtype binding requires the presence of the DOR-1 gene. Front. Biosci. (Schol. Ed.) 2010, 2, 772-780.
71. Xie, Z.; Bhushan, R.G.; Daniels, D.J.; Portoghese, P.S. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. Mol. Pharmacol. 2005, 68, 1079-1086.
72. Sharma, S.K.; Jones, R.M.; Metzger, T.G.; Ferguson, D.M.; Portoghese, P.S. Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole. J. Med. Chem. 2001, 44, 2073-2079.
73. Rowan, M.P.; Ruparel, N.B.; Patwardhan, A.M.; Berg, K.A.; Clarke, W.P.; Hargreaves, K.M. Peripheral delta opioid receptors require priming for functional competence in vivo. Eur. J. Pharmacol. 2009, 602, 283-287.
74. Berg, K.A.; Rowan, M.P.; Sanchez, T.A.; Silva, M.; Patwardhan, A.M.; Milam, S.B.; Hargreaves, K.M.; Clarke, W.P. Regulation of kappa-opioid receptor signaling in peripheral sensory neurons in vitro and in vivo. J. Pharmacol. Exp. Ther. 2011, 338, 92-99.
75. Chakrabarti, S.; Liu, N.J.; Gintzler, A.R. Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proc. Natl. Acad. Sci. USA 2010, 107, 20115-20119.
76. Yekkirala, A.S.; Kalyuzhny, A.E.; Portoghese, P.S. Standard opioid agonists activate heteromeric opioid receptors: Evidence for morphine and D-Ala(2)-MePhe(4)-Glyol(5) enkephalin as selective mu-delta agonists. ACS Chem. Neurosci. 2010, 1, 146-154.
77. Liu, N.J.; Chakrabarti, S.; Schnell, S.; Wessendorf, M.; Gintzler, A.R. Spinal synthesis of estrogen and concomitant signaling by membrane estrogen receptors regulate spinal kappa- and mu-opioid receptor heterodimerization and female-specific spinal morphine antinociception. J. Neurosci. 2011, 31, 11836-11845.
78. Fillingim, R.B.; Gear, R.W. Sex differences in opioid analgesia: Clinical and experimental findings. Eur. J. Pain 2004, 8, 413-425.
79. Gear, R.W.; Gordon, N.C.; Heller, P.H.; Paul, S.; Miaskowski, C.; Levine, J.D. Gender difference in analgesic response to the kappa-opioid pentazocine. Neurosci. Lett. 1996, 205, 207-209.
80. Gear, R.W.; Miaskowski, C.; Gordon, N.C.; Paul, S.M.; Heller, P.H.; Levine, J.D. Kappa-opioids produce significantly greater analgesia in women than in men. Nat. Med. 1996, 2, 1248-1250.
81. Gear, R.W.; Miaskowski, C.; Gordon, N.C.; Paul, S.M.; Heller, P.H.; Levine, J.D. The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 1999, 83, 339-345.
82. Liu, N.J.; von Gizycki, H.; Gintzler, A.R. Sexually dimorphic recruitment of spinal opioid analgesic pathways by the spinal application of morphine. J. Pharmacol. Exp. Ther. 2007, 322, 654-660.
83. Fairbanks, C.A.; Stone, L.S.; Wilcox, G.L. Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis. Pharmacol. Ther. 2009, 123, 224-238.
84. Stone, L.S.; MacMillan, L.B.; Kitto, K.F.; Limbird, L.E.; Wilcox, G.L. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J. Neurosci. 1997, 17, 7157-7165.
85. Mansikka, H.; Lähdesmäki, J.; Scheinin, M.; Pertovaara, A. Alpha(2A) adrenoceptors contribute to feedback inhibition of capsaicin-induced hyperalgesia. Anesthesiology 2004, 101, 185-190.
86. Spaulding, T.C.; Fielding, S.; Venafro, J.J.; Lal, H. Antinociceptive activity of clonidine and its potentiation of morphine analgesia. Eur. J. Pharmacol. 1979, 58, 19-25.
87. Wilcox, G.L.; Carlsson, K.-H.; Jochim, A.; Jurna I. Mutual potentiation of antinociceptive effects of morphine and clonidine on motor and sensory responses in rat spinal cord. Brain Res. 1987, 405, 84-93.
88. Drasner, K.; Fields, H.L. Synergy between the antinociceptive effects of intrathecal clonidine and systemic morphine in the rat. Pain 1988, 32, 309-312.
89. Jordan, B.A.; Gomes, I.; Rios, C.; Filipovska, J.; Devi, L.A. Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol. Pharmacol. 2003, 64, 1317-1324.
90. Zhang, Y.Q.; Limbird, L.E. Hetero-oligomers of alpha2A-adrenergic and mu-opioid receptors do not lead to transactivation of G-proteins or altered endocytosis profiles. Biochem. Soc. Trans. 2004, 32, 856-860.
91. Vilardaga, J.P.; Nikolaev, V.O.; Lorenz, K.; Ferrandon, S.; Zhuang, Z.; Lohse, M.J. Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat. Chem. Biol. 2008, 4, 126-131.
92. Riedl, M.S.; Schnell, S.A.; Overland, A.C.; Chabot-Doré, A.J.; Taylor, A.M.; Ribeiro-da-Silva, A.; Elde, R.P.; Wilcox, G.L.; Stone, LS. Coexpression of alpha 2A-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn. J. Comp. Neurol. 2009, 513, 385-398.
93. Clapper, J.R.; Moreno-Sanz, G.; Russo, R.; Guijarro, A.; Vacondio, F.; Duranti, A.; Tontini, A.; Sanchini, S.; Sciolino, N.R.; Spradley, J.M. et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 2010, 13, 1265-1270.
94. Vigano, D.; Rubino, T.; Parolaro, D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol. Biochem. Behav. 2005, 81, 360-368.
95. Filppula, S.; Yaddanapudi, S.; Mercier, R.; Xu, W.; Pavlopoulos, S.; Makriyannis A. Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system. J. Pept. Res. 2004, 64, 225-236.
96. Rios, C.; Gomes, I.; Devi, L.A. Mu opioid and CB1 cannabinoid receptor interactions: Reciprocal inhibition of receptor signaling and neuritogenesis. Br. J. Pharmacol. 2006, 148, 387-395.
97. Salio, C.; Fischer, J.; Franzoni, M.F.; Mackie, K.; Kaneko, T.; Conrath, M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 2001, 12, 3689-3692.
98. Hohmann, A.G.; Briley, E.M.; Herkenham, M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 1999, 822, 17-25.
99. Rodriguez, J.J.; Mackie, K.; Pickel, V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J. Neurosci. 2001, 21, 823-833.
100. Pickel, V.M.; Chan, J.; Kash, T.L.; Rodríguez, J.J.; MacKie, K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 2004, 127, 101-112.
101. Cichewicz, D.L.; McCarthy, E.A. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J. Pharmacol. Exp. Ther. 2003, 304, 1010-1015.
102. Cichewicz, D.L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 2004, 74, 1317-1324.
103. Sun, Y.G.; Chen, Z.F. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007, 448, 700-703.
104. Sun, Y.G.; Zhao, Z.-Q.; Meng, X.-L.; Yin, J.; Liu, X.-Y.; Chen, Z.-F. Cellular basis of itch sensation. Science 2009, 325, 1531-1534.
105. Liu, X.Y.; Liu, Z.-C.; Sun, Y.-G.; Ross, M.; Kim, S.; Tsai, F.-F.; Li, Q.-F.; Jeffry, J.; Kim, J.-Y.; Loh, H.H.; et al. Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 2011, 147, 447-458.
106. Melzack, R.; Wall, P.D. Pain mechanisms: A new theory. Science 1965, 150, 971-979.
107. Yaksh, T.L. Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: Effects of modulatory receptor systems and excitatory amino acid antagonists. Pain 1989, 37, 111-123.
108. Zeilhofer, H.U. Loss of glycinergic and GABAergic inhibition in chronic pain--contributions of inflammation and microglia. Int. Immunopharmacol. 2008, 8, 182-187.
109. Bohlhalter, S.; Weinmann, O.; Mohler, H.; Fritschy, J.M. Laminar compartmentalization of GABAA-receptor subtypes in the spinal cord: An immunohistochemical study. J. Neurosci. 1996, 16, 283-297.
110. Scholz, J.; Broom, D.C.; Youn, D.-H.; Mills, C.D.; Kohno, T.; Suter, M.R.; Moore, K.A.; Decosterd, I.; Coggeshall, R.E.; Woolf, C.J. Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J. Neurosci. 2005, 25, 7317-7323.
111. Tucker, A.P.; Mezzatesta, J.; Nadeson, R.; Goodchild, C.S. Intrathecal midazolam II: Combination with intrathecal fentanyl for labor pain. Anesth. Analg. 2004, 98, 1521-1527.
112. Jasmin, L.; Wu, M.V.; Ohara, P.T. GABA puts a stop to pain. Curr. Drug. Targets CNS Neurol. Disord. 2004, 3, 487-505.
113. Wieland, H.A.; Luddens, H.; Seeburg, P.H. A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J. Biol. Chem. 1992, 267, 1426-1429.
114. Rudolph, U.; Mohler, H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr. Opin. Pharmacol. 2006, 6, 18-23.
115. Knabl, J.; Witschi, R.; Hösl, K.; Reinold, H.; Zeilhofer, U.B.; Ahmadi, S.; Brockhaus, J.; Sergejeva, M.; Hess, A.; Brune, K. et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008, 451, 330-334.
116. Witschi, R.; Punnakkal, P.; Paul, J.; Walczak, J.S.; Cervero, F.; Fritschy, J.M.; Kuner, R.; Keist, R.; Rudolph, U.; Zeilhofer, H.U. Presynaptic alpha2-GABAA receptors in primary afferent depolarization and spinal pain control. J. Neurosci. 2011, 31, 8134-8142.
117. Yanovsky, Y.; Schubring, S.; Fleischer, W.; Gisselmann, G.; Zhu, X.R.; Lübbert, H.; Hatt, H.; Rudolph, U.; Haas, H.L.; Sergeeva, O.A. GABA(A) receptors involved in sleep and anaesthesia: β1- versus β3-Containing assemblies. Pflugers Arch. 2011, 463, 187-199.
118. Rudolph, U.; Knoflach, F. Beyond classical benzodiazepines: Novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 2011, 10, 685-697.
119. Atack, J.R.; Wafford, K.A.; Tye, S.J.; Cook, S.M.; Sohal, B.; Pike, A.; Sur, C.; Melillo, D.; Bristow, L.; Bromidge, F. et al. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3- ylmethoxy)-3-(2-fluor ophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J. Pharmacol. Exp. Ther. 2006, 316, 410-422.
120. Griebel, G.; Perrault, G.; Simiand, J.; Cohen, C.; Granger, P.; Depoortere, H.; Françon, D.; Avenet, P.; Schoemaker, H.; Evanno, Y. et al. lSL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Rev. 2003, 9, 3-20.
121. Sonner, J.M.; Cascio, M.; Xing, Y.; Fanselow, M.S.; Kralic, J.E.; Morrow, A.L.; Korpi, E.R.; Hardy, S.; Sloat, B.; Eger, E.I., II; et al. Alpha 1 subunit-containing GABA type A receptors in forebrain contribute to the effect of inhaled anesthetics on conditioned fear. Mol. Pharmacol. 2005, 68, 61-68.
122. Caraiscos, V.B.; Elliott, E.M.; You-Ten, K.E.; Cheng, V.Y.; Belelli, D.; Newell, J.G.; Jackson, M.F.; Lambert, J.J.; Rosahl, T.W.; Wafford, K.A. et al. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A receptors. Proc. Natl. Acad. Sci. USA 2004, 101, 3662-3667.
123. Mirza, N.R.; Nielsen, E.O. Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice? J. Pharmacol. Exp. Ther. 2006, 316, 1378-1385.
124. Finnerup, N.B.; Otto, M.; McQuay, H.J.; Jensen, T.S.; Sindrup, S.H. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005, 118, 289-305.
125. Albuquerque, E.X.; Pereira, E.F.R.; Alkondon, M.; Rogers, S.W. Mammalian nicotinic acetylcholine receptors: From structure to function. Physiol. Rev. 2009, 89, 73-120.
126. Johnson, D.S.; Martinez, J.; Elgoyhen, A.B.; Heinemann, S.F.; McIntosh, J.M. Alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: Preferential inhibition of homomeric alpha 7 and alpha 9 receptors. Mol. Pharmacol. 1995, 48, 194-199.
127. Elgoyhen, A.B.; Johnson, D.S.; Boulter, J.; Vetter, D.E.; Heinemann, S. alpha 9: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994, 79, 705-715.
128. Elgoyhen, A.B.; Vetter, D.E.; Katz, E.; Rothlin, C.V.; Heinemann, S.F.; Boulter, J. alpha10: A determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc. Natl. Acad. Sci. USA 2001, 98, 3501-3506.
129. Gotti, C.; Riganti, L.; Vailati, S.; Clementi, F. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr. Pharm. Des. 2006, 12, 407-428.
130. Olivera, B.M.; Quik, M.; Vincler, M.; McIntosh, J.M. Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applications. Channels (Austin) 2008, 2, 143-152.
131. Decker, M.W.; Meyer, M.D.; Sullivan, J.P. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin. Investig. Drugs 2001, 10, 1819-1830.
132. Dray, A. Neuropathic pain: Emerging treatments. Br. J. Anaesth. 2008, 101, 48-58.
133. Ellison, M.; Haberlandt, C.; Gomez-Casati, M.E.; Watkins, M.; Elgoyhen, A.B.; McIntosh, J.M.; Olivera, B.M. Alpha-RgIA: A novel conotoxin that specifically and potently blocks the alpha9alpha10 nAChR. Biochemistry 2006, 45, 1511-1517.
134. Sandall, D.W.; Satkunanathan, N.; Keays, D.A.; Polidano, M.A.; Liping, X.; Pham, V.; Down, J.G.; Khalil, Z.; Livett, B.G.; Gayler, K.R. A novel alpha-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry 2003, 42, 6904-6911.
135. Vincler, M.; Wittenauer, S.; Parker, R.; Ellison, M.; Olivera, B.M.; McIntosh, J.M. Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors. Proc. Natl. Acad. Sci. USA 2006, 103, 17880-17884.
136. Callaghan, B.; Haythornthwaite, A.; Berecki, G.; Clark, R.J.; Craik, D.J.; Adams, D.J. Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation. J. Neurosci. 2008, 28, 10943-10951.
137. Callaghan, B.; Adams, D.J. Analgesic alpha-conotoxins Vc1.1 and RgIA inhibit N-type calcium channels in sensory neurons of alpha9 nicotinic receptor knockout mice. Channels (Austin) 2011, 4, 51-54.
138. McIntosh, J.M.; Absalom, N.; Chebib, M.; Elgoyhen, A.B.; Vincler, M. Alpha9 nicotinic acetylcholine receptors and the treatment of pain. Biochem. Pharmacol. 2009, 78, 693-702.
139. Watkins, J.C.; Evans, R.H. Excitatory amino acid transmitters. Annu. Rev. Pharmacol. Toxicol. 1981, 21, 165-204.
140. Watkins, J.C.; Davies, J.; Evans, R.H.; Francis, A.A.; Jones, A.W. Pharmacology of receptors for excitatory amino acids. Adv. Biochem. Psychopharmacol. 1981, 27, 263-273.
141. Szekely, J.I.; Torok, K.; Mate, G. The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites. Curr. Pharm. Des. 2002, 8, 887-912.
142. Neugebauer, V. Glutamate receptor ligands. Handb. Exp. Pharmacol. 2007, 177, 217-249.
143. Hollmann, M.; Heinemann, S. Cloned glutamate receptors. Annu. Rev. Neurosci. 1994, 17, 31-108.
144. Mano, I.; Teichberg, V.I. A tetrameric subunit stoichiometry for a glutamate receptor-channel complex. Neuroreport 1998, 9, 327-331.
145. Premkumar, L.S.; Auerbach, A. Stoichiometry of recombinant N-methyl-D-aspartate receptor channels inferred from single-channel current patterns. J. Gen. Physiol. 1997, 110, 485-502.
146. Cull-Candy, S.; Brickley, S.; Farrant, M. NMDA receptor subunits: Diversity, development and disease. Curr. Opin. Neurobiol. 2001, 11, 327-335.
147. Furukawa, H.; Singh, S.K.; Mancusso, R.; Gouaux, E. Subunit arrangement and function in NMDA receptors. Nature 2005, 438, 185-192.
148. Constantine-Paton, M.; Cline, H.T. LTP and activity-dependent synaptogenesis: The more alike they are, the more different they become. Curr. Opin. Neurobiol. 1998, 8, 139-148.
149. Quartaroli, M.; Fasdelli, N.; Bettelini, L.; Maraia, G.; Corsi, M. GV196771A, an NMDA receptor/glycine site antagonist, attenuates mechanical allodynia in neuropathic rats and reduces tolerance induced by morphine in mice. Eur. J. Pharmacol. 2001, 430, 219-227.
150. Wallace, M.S.; Rowbotham, M.C.; Katz, N.P.; Dworkin, R.H.; Dotson, R.M.; Galer, B.S.; Rauck, R.L.; Backonja, M.M.; Quessy, S.N.; Meisner, P.D. A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology 2002, 59, 1694-1700.
151. Gogas, K.R. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr. Opin. Pharmacol. 2006, 6, 68-74.
152. Taniguchi, K.; Shinjo, K.; Mizutani, M.; Shimada, K.; Ishikawa, T.; Menniti, F.S.; Nagahisa, A. Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br. J. Pharmacol. 1997, 122, 809-812.
153. Sang, C.N.; Ramadan, N.M.; Wallihan, R.G.; Chappell, A.S.; Freitag, F.G.; Smith, T.R.; Silberstein, S.D.; Johnson, K.W.; Phebus, L.A.; Bleakman, D.; et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004, 24, 596-602.
154. Sang, C.N.; Hostetter, M.P.; Gracely, R.H.; Chappell, A.S.; Schoepp, D.D.; Lee, G.; Whitcup, S.; Caruso, R.; Max, M.B. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 1998, 89, 1060-1067.
155. North, R.A. Molecular physiology of P2X receptors. Physiol. Rev. 2002, 82, 1013-1067.
156. Jiang, L.H.; Kim, M.; Spelta, V.; Bo, X.; Surprenant, A.; North, R.A. Subunit arrangement in P2X receptors. J. Neurosci. 2003, 23, 8903-8910.
157. Ding, S.; Sachs, F. Inactivation of P2X2 purinoceptors by divalent cations. J. Physiol. 2000, 522, 199-214.
158. Lewis, C.; Neidhart, S.; Holy, C.; North, R.A.; Buell, G.; Surprenant, A. Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature 1995, 377, 432-435.
159. Torres, G.E.; Haines, W.R.; Egan, T.M.; Voigt, M.M. Co-expression of P2X1 and P2X5 receptor subunits reveals a novel ATP-gated ion channel. Mol. Pharmacol. 1998, 54, 989-993.
160. Jarvis, M.F.; Khakh, B.S. ATP-gated P2X cation-channels. Neuropharmacology 2009, 56, 208-215.
161. Chessell, I.P.; Hatcher, J.P.; Bountra, C.; Michel, A.D.; Hughes, J.P.; Green, P.; Egerton, J.; Murfin, M.; Richardson, J.; Peck, W.L.; et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005, 114, 386-396.
162. Tsuda, M.; Shigemoto-Mogami, Y.; Koizumi, S.; Mizokoshi, A.; Kohsaka, S.; Salter, M.W.; Inoue, K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003, 424, 778-783.
163. Clapham, D.E. TRP channels as cellular sensors. Nature 2003, 426, 517-524.
164. Jordt, S.E.; McKemy, D.D.; Julius, D. Lessons from peppers and peppermint: The molecular logic of thermosensation. Curr. Opin. Neurobiol. 2003, 13, 487-492.
165. Ramsey, I.S.; Delling, M.; Clapham, D.E. An introduction to trp channels. Annu. Rev. Physiol. 2006, 68, 619-647.
166. Garcia-Sanz, N.; Fernández-Carvajal, A.; Morenilla-Palao, C.; Planells-Cases, R.; Fajardo-Sánchez, E.; Fernández-Ballester, G.; Ferrer-Montiel, A. Identification of a tetramerization domain in the C terminus of the vanilloid receptor. J. Neurosci. 2004, 24, 5307-5314.
167. Zhang, F.; Liu, S.; Yang, F.; Zheng, J.; Wang, K.W. Identification of a tetrameric assembly domain in the C terminus of heat-activated TRPV1 channels. J. Biol. Chem. 2011, 286, 15308-15316.
168. Hofmann, T.; Schaefer, M.; Schultz, G.; Gudermann, T. Subunit composition of mammalian transient receptor potential channels in living cells. Proc. Natl. Acad. Sci. USA 2002, 99, 7461-7466.
169. Strubing, C.; Krapivinsky, G.; Krapivinsky, L.; Clapham, D.E. Formation of novel TRPC channels by complex subunit interactions in embryonic brain. J. Biol. Chem. 2003, 278, 39014-39019.
170. Goel, M.; Sinkins, W.G.; Schilling, W.P. Selective association of TRPC channel subunits in rat brain synaptosomes. J. Biol. Chem. 2002, 277, 48303-48310.
171. Rutter, A.R.; Ma, Q.P.; Leveridge, M.; Bonnert, T.P. Heteromerization and colocalization of TrpV1 and TrpV2 in mammalian cell lines and rat dorsal root ganglia. Neuroreport 2005, 16, 1735-1739.
172. Smith, G.D.; Gunthorpe, M.J.; Kelsell, R.E.; Hayes, P.D.; Reilly, P.; Facer, P.; Wright, J.E.; Jerman, J.C.; Walhin, J.P.; Ooi, L.; et al. TRPV3 is a temperature-sensitive vanilloid receptor- like protein. Nature 2002, 418, 186-190.
173. Cheng, W.; Yang, F.; Liu, S.; Colton, C.K.; Wang, C.; Cui, Y.Y.; Cao, X.; Zhu, M.X.; Sun, C.S.; Wang, K.W.; et al. Heteromeric heat-sensitive TRP channels exhibit distinct temperature and chemical response. J. Biol. Chem. 2011, doi:10.1074/jbc.M111.305045.
174. Chubanov, V.; Waldegger, S.; Schnitzler, M.M.; Vitzthum, H.; Sassen, M.C.; Seyberth, H.W.; Konrad, M.; Gudermann, T. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc. Natl. Acad. Sci. USA 2004, 101, 2894-2899.
175. Xu, H.; Ramsey, I.S.; Kotecha, S.A.; Moran, M.M.; Chong, J.A.; Lawson, D.; Ge, P.; Lilly, J.; Silos-Santiago, I.; Xie, Y.; et al. TRPV3 is a calcium-permeable temperature-sensitive cation channel. Nature 2002, 418, 181-186.
176. Cheng, W.; Yang, F.; Takanishi, C.L.; Zheng, J. Thermosensitive TRPV channel subunits coassemble into heteromeric channels with intermediate conductance and gating properties. J. Gen. Physiol. 2007, 129, 191-207.
177. Latorre, R.; Brauchi, S.; Orta, G.; Zaelzer, C.; Vargas, G. ThermoTRP channels as modular proteins with allosteric gating. Cell Calcium 2007, 42, 427-438.
178. Akopian, A.N.; Ruparel, N.B.; Patwardhan, A.; Hargreaves, K.M. Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J. Neurosci. 2008, 28, 1064-1075.
179. Patil, M.; Patwardhan, A.; Salas, M.M.; Hargreaves, K.M.; Akopian, A.N. Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons. Neuropharmacology 2011, 61, 778-788.
180. Bobanovic, L.K.; Royle, S.J.; Murrell-Lagnado, R.D. P2X receptor trafficking in neurons is subunit specific. J. Neurosci. 2002, 22, 4814-4824.
181. Arniges, M.; Fernández-Fernández, J.M.; Albrecht, N.; Schaefer, M.; Valverde, M.A. Human TRPV4 channel splice variants revealed a key role of ankyrin domains in multimerization and trafficking. J. Biol. Chem. 2006, 281, 1580-1586.
182. Ambudkar, I.S. Trafficking of TRP channels: Determinants of channel function. Handb. Exp. Pharmacol. 2007, 179, 541-557.
183. Pfeiffer, M.; Kirscht, S.; Stumm, R.; Koch, T.; Wu, D.; Laugsch, M.; Schröder, H.; Höllt, V.; Schulz, S. Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization. J. Biol. Chem. 2003, 278, 51630-51637.
184. Haas, K.F.; Macdonald, R.L. GABAA receptor subunit gamma2 and delta subtypes confer unique kinetic properties on recombinant GABAA receptor currents in mouse fibroblasts. J. Physiol. 1999, 514, 27-45.
185. Akopian, A.N.; Ruparel, N.B.; Jeske, N.A.; Patwardhan, A.; Hargreaves, K.M. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol. Sci. 2009, 30, 79-84.
186. Bautista, D.M.; Jordt, S.E.; Nikai, T.; Tsuruda, P.R.; Read, A.J.; Poblete, J.; Yamoah, E.N.; Basbaum, A.I.; Julius, D. TRPA1 Mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 2006, 124, 1269-1282.
187. Kang, K.; Pulver, S.R.; Panzano, V.C.; Chang, E.C.; Griffith, L.C.; Theobald, D.L.; Garrity, P.A. Analysis of drosophila TRPA1 reveals an ancient origin for human chemical nociception. Nature 2010, 464, 597-600.
188. Gracheva, E.O.; Ingolia, N.T.; Kelly, Y.M.; Cordero-Morales, J.F.; Hollopeter, G.; Chesler, A.T.; Sánchez, E.E.; Perez, J.C.; Weissman, J.S.; Julius, D. Molecular basis of infrared detection by snakes. Nature 2010, 464, 1006-1011.
189. Patil, M.J.; Belugin, S.; Akopian, A.N. Chronic alteration in phosphatidylinositol 4,5-biphosphate levels regulates capsaicin and mustard oil responses. J. Neurosci. Res. 2011, 89, 945-954.
190. Diogenes, A.; Akopian, A.N.; Hargreaves, K.M. NGF up-regulates TRPA1: Implications for orofacial pain. J. Dent. Res. 2007, 86, 550-555.
191. Patacchini, R.; Maggi, C.A.; Meli, A. Capsaicin-like activity of some natural pungent substances on peripheral endings of visceral primary afferents. Naunyn Schmiedebergs Arch. Pharmacol. 1990, 342, 72-77.
192. Ruparel, N.B.; Patwardhan, A.M.; Akopian, A.N.; Hargreaves, K.M. Homologous and heterologous desensitization of capsaicin and mustard oil responses utilize different cellular pathways in nociceptors. Pain 2008,135, 271-279.
193. Jacquot, L.; Monnin, J.; Lucarz, A.; Brand, G. Trigeminal sensitization and desensitization in the nasal cavity: A study of cross interactions. Rhinology 2005, 43, 93-98.
194. Simons, C.T.; Sudo, S.; Sudo, M.; Carstens, E. Mustard oil has differential effects on the response of trigeminal caudalis neurons to heat and acidity. Pain 2004, 110, 64-71.
195. Bandell, M.; Story, G.M.; Hwang, S.W.; Viswanath, V.; Eid, S.R.; Petrus, M.J.; Earley, T.J.; Patapoutian, A. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 2004, 41, 849-857.
196. Kollarik, M.; Undem, B.J. Activation of bronchopulmonary vagal afferent nerves with bradykinin, acid and vanilloid receptor agonists in wild-type and TRPV1 mice. J. Physiol. 2004, 555, 115-123.
197. Dziedzicka-Wasylewska, M.; Faron-Górecka, A.; Górecki, A.; Kuśemider, M. Mechanism of action of clozapine in the context of dopamine D1-D2 receptor hetero-dimerization-A working hypothesis. Pharmacol. Rep. 2008, 60, 581-587.
198. Jorenby, D.E.; Hays, J.T.; Rigotti, N.A.; Azoulay, S.; Watsky, E.J.; Williams, K.E.; Billing, C.B.; Gong, J.; Reeves, K.R.; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006, 296, 56-63.
199. Maggio, R.; Barbier, P.; Colelli, A.; Salvadori, F.; Demontis, G.; Corsini, G.U. G protein-linked receptors: Pharmacological evidence for the formation of heterodimers. J. Pharmacol. Exp. Ther. 1999, 291, 251-257.
200. Ciruela, F.; Casadó, V.; Rodrigues, R.J.; Luján, R.; Burgueño, J.; Canals, M.; Borycz, J.; Rebola, N.; Goldberg, S.R.; Mallol, J.; et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci. 2006, 26, 2080-2087.
201. Gabitzsch, E.S.; Xu, Y.N.; Balcaitis, S.; Balint, J.P., Jr.; Jones, F.R. An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Ther. 2011, 18, 326-335.
202. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346, 818-822.
203. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505-510.
204. Park, J.S.; Wang, C.Z.; Han, Y.; Huang, Z.; Niu, L. Potent and selective inhibition of a single alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid(AMPA) receptor subunit by an RNA aptamer. J. Biol. Chem. 2011, 286, 15608-15617.
205. Chen, C.H.; Chernis, G.A.; Hoang, V.Q.; Landgraf, R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl. Acad. Sci. USA 2003, 100, 9226-9231.